Scilex Holding Company Stock-Based Compensation
Scilex Holding Company (SCLX) reported Stock-Based Compensation of $7.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Scilex Holding Company share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.60M, a 9.64% increase year-over-year.
- Scilex Holding Company share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.63M, a 9.51% increase year-over-year.
- Scilex Holding Company share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.64M, a 17.44% increase year-over-year.
- Scilex Holding Company share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.26M, a 12.31% decline year-over-year.
- Scilex Holding Company share-based payment arrangement, noncash expense for fiscal 2025 was $15.49M, a 1.26% decline from fiscal 2024.
- Scilex Holding Company share-based payment arrangement, noncash expense for fiscal 2024 was $15.69M, a 7.49% increase from fiscal 2023.
- Scilex Holding Company share-based payment arrangement, noncash expense for fiscal 2023 was $14.60M, a 176.44% increase from fiscal 2022.
- Scilex Holding Company share-based payment arrangement, noncash expense for fiscal 2022 was $5.28M, a 9.31% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $7.22M 10-Q · filed 2026-08-14 | $12.87M derived: sum of 3 quarters · filed 2026-08-14 | $16.12M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $3.63M 10-Q · filed 2026-05-20 | $9.27M derived: sum of 2 quarters · filed 2026-05-20 | $12.53M derived: sum of 3 quarters · filed 2026-05-20 | $15.81M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $5.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $8.90M derived: sum of 2 quarters · filed 2026-04-10 | $12.18M derived: sum of 3 quarters · filed 2026-04-10 | $15.49M 10-K · filed 2026-04-10 |
| 2025-09-30 | $3.26M 10-Q · filed 2025-11-14 | $6.54M derived: sum of 2 quarters · filed 2025-11-14 | $9.85M 10-Q · filed 2025-11-14 | $14.65M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $3.28M 10-Q · filed 2025-11-14 | $6.59M 10-Q · filed 2026-08-14 | $11.40M derived: sum of 3 quarters · filed 2026-05-20 | $15.11M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $3.31M 10-Q · filed 2026-05-20 | $8.12M derived: sum of 2 quarters · filed 2026-05-20 | $11.83M derived: sum of 3 quarters · filed 2026-05-20 | $15.45M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $8.52M derived: sum of 2 quarters · filed 2026-04-10 | $12.13M derived: sum of 3 quarters · filed 2026-04-10 | $15.69M 10-K · filed 2026-04-10 |
| 2024-09-30 | $3.71M 10-Q · filed 2025-11-14 | $7.33M derived: sum of 2 quarters · filed 2025-11-14 | $10.88M 10-Q · filed 2025-11-14 | $14.67M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.61M 10-Q · filed 2025-11-14 | $7.17M 10-Q · filed 2025-08-13 | $10.95M derived: sum of 3 quarters · filed 2025-11-14 | $14.46M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-03-31 | $3.56M 10-Q · filed 2025-11-14 | $7.34M derived: sum of 2 quarters · filed 2025-11-14 | $10.85M derived: sum of 3 quarters · filed 2025-11-14 | $14.43M derived: sum of 4 quarters · filed 2025-11-14 |
| 2023-12-31 | $3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.29M derived: sum of 2 quarters · filed 2025-03-31 | $10.88M derived: sum of 3 quarters · filed 2025-03-31 | $14.60M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $7.09M derived: sum of 2 quarters · filed 2025-01-17 | $10.81M 10-Q · filed 2025-01-17 | $12.07M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $3.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $7.31M 10-Q · filed 2024-08-13 | $8.56M derived: sum of 3 quarters · filed 2024-08-13 | $9.79M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $3.72M 10-Q · filed 2024-05-13 | $4.97M derived: sum of 2 quarters · filed 2024-05-13 | $6.21M derived: sum of 3 quarters · filed 2024-05-13 | $7.64M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.49M derived: sum of 2 quarters · filed 2024-03-12 | $3.92M derived: sum of 3 quarters · filed 2024-03-12 | $5.28M 10-K · filed 2024-03-12 |
| 2022-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.67M derived: sum of 2 quarters · filed 2023-11-14 | $4.03M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $2.79M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $1.35M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $5.82M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $5.39M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |